Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
CONTEXT: Endogenous glucocorticoid excess (Cushing's syndrome) predominantly increases postprandial glucose concentration. The pattern of hyperglycemia induced by prednisolone has not been well characterized. OBJECTIVE: Our objective was to define the circadian effect of prednisolone on glucose concentration to optimize management of prednisolone-induced hyperglycemia. DESIGN AND SETTING: This was a cross-sectional study in a teaching hospital. PARTICIPANTS: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 ± 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 ± 9 mg/d). MAIN OUTCOME MEASURE: Interstitial glucose concentration was assessed during continuous glucose monitoring. RESULTS: Significantly more subjects in group 2 [21 of 40 (53%), P = 0.02] and group 3 [seven of seven (100%), P = 0.003] recorded a glucose of at least 200 mg/dl (≥11.1 mmol/liter) during continuous glucose monitoring than in group 1 [one of 13 (8%)]. The mean glucose concentration between 2400-1200 h for group 3 (142 ± 36 mg/dl) was significantly greater than in the other two groups (P < 0.005), whereas mean glucose concentrations between 2400-1200 h in group 1 (108 ± 16 mg/dl) and group 2 (112 ± 22 mg/dl) were not significantly different. In contrast, the mean glucose concentrations between 1200-2400 h for group 2 (142 ± 25 mg/dl) and group 3 (189 ± 32 mg/dl) were both significantly greater than group 1 (117 ± 14 mg/dl, P < 0.05 for both comparisons). CONCLUSIONS: Prednisolone predominantly causes hyperglycemia in the afternoon and evening. Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rates of severe hypoglycemia events in ambulatory persons with end-stage kidney disease on dialysis are 10-fold higher than among other nondialysis persons with CKD and often associated with prolonged hypoglycemic episodes and poor response to regular hypoglycemia treatment.1375”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1375]
In the citing paper
“These findings are in line with previous reports of afternoon and evening hyperglycaemia under glucocorticoids in persons without DM.24 27 55”
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444 · cited 3×
“As such, currently, we would not support routine glucose lowering in patients with mild prednisolone-induced hyperglycemia but recommend individualized decision making based on the severity and duration of hyperglycemia, aiming to maintain blood glucose from 72–180 mg/dl (4–10 mmol/liter), in line with general recomme…”
BackgroundInfluentialDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“However, endogenous glucocorticoid excess in Cushing’s syndrome predominantly increases postprandial blood glucose concentration with fasting glucose often in the normal range (8).”
BackgroundKrinsley, J. S. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.12.1471 · Cited by 1,165
Weir, C. J., Murray, G. D., Dyker, A. G., & Lees, K. R. (1997) · BMJ · doi:10.1136/bmj.314.7090.1303 · Cited by 522 · cited 2×
“Hyperglycemic Effect of Glucocorticoids J Clin Endocrinol Metab, June 2011, 96(6):1789–1796”
BackgroundGlucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Deedwania, P., Kosiborod, M., Barrett, E., Ceriello, A., Isley, W., Mazzone, T., & Raskin, P. (2008) · Circulation · doi:10.1161/circulationaha.107.188629 · Cited by 488
Limitations of Conventional Methods of Self-Monitoring of Blood Glucose
Boland, E., Monsod, T., Delucia, M., Brandt, C. A., Fernando, S., & Tamborlane, W. V. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1858 · Cited by 423 · cited 1×
“CGMS provide detailed information regarding nocturnal and postprandial glycemia, whereas standard finger-prick blood glucose monitoring regimens do not (11).”
BackgroundBaker, E. H. (2006) · Thorax · doi:10.1136/thx.2005.051029 · Cited by 418
Cited by
Items 101–200 of 202
Brinchault, G., Diot, P., Dixmier, A., Goupil, F., Guillais, P., Gut‐Gobert, C., Leroyer, C., Marchand-Adam, S., Meurice, J.-C., Morel, H., et al. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2015.09.009 · Cited by 15
Hyperglycemia in Severe and Critical COVID-19 Patients: Risk Factors and Outcomes
Le, V. T., Hung, H. M. J., Tran, M., Le, N. T., Le, V. T., & Le, K. M. (2022) · Cureus · doi:10.7759/cureus.27611 · Cited by 14
“Previous studies showed that 53-70% of non-diabetic individuals developed steroid-induced hyperglycemia after being treated with high-dose corticosteroids [24,25].”
BackgroundKonservative Therapie der „frozen shoulder“
Franz, A. R., Klose, M., & Beitzel, K. (2019) · Der Unfallchirurg · doi:10.1007/s00113-019-00731-3 · Cited by 10
“Da oral eingenommene Glukokortikoide einerseits die Insulinresistenz fördern, eine Dysfunktion der Inselzellen des Pankreas unterstützen sowie dadurch Erhöhungen des Nüchtern- und postprandialen Glucosespiegels induzieren [7, 28], können jene Nebenwirkungen durch per IAI angewandte Steroide reduziert werden.”
BackgroundSamimi, Z., Izadpanah, A., Feizollahi, P., Roghani, S. A., Assar, S., Zafari, P., & Taghadosi, M. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1781160 · Cited by 9
“Furthermore, glucocorticoids abundantly used in the treatment of RA worsen glucose tolerance through the induction of gluconeogenesis by the liver and inhibition of glucose uptake by adipocytes(Burt et al. 2011).”
BackgroundSingle-dose prednisolone alters endocrine and haematologic responses and exercise performance in men
Tacey, A., Parker, L., Yeap, B. B., Joseph, J., Lim, E. M., GARNHAM, A. P., Hare, D. L., Brennan‐Speranza, T. C., & Levinger, I. (2019) · Endocrine Connections · doi:10.1530/ec-18-0473 · Cited by 11
Sweeting, A., Hsieh, A., Wong, J., & Ross, G. P. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1900104 · Cited by 9
Effets indésirables métaboliques et cardiovasculaires des corticothérapies systémiques
Fardet, L. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.12.005 · Cited by 13
Achieving Glycemic Control in Special Populations in Hospital: Perspectives in Practice
CHENG, A. Y. Y. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.02.021 · Cited by 10
Véber, O. Á., Wilde, A., Demeter, J., Tamás, G., Mucsi, I., & Tabák, Á. G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-013-0027-8 · Cited by 9
“[9] had no controls for their type 2 diabetes group, as all diabetes patients were treated with prednisolone.”
BackgroundResultInfluentialToyoshima, M. T. K., Cukier, P., de Souza, A. B. C., Pereira, J. C., Hoff, A. O., & Nery, M. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022ao8031 · Cited by 9
“1mmol/L).(14) Glucocorticoids are important drugs in cancer treatment.”
BackgroundResultInfluentialGolubić, R., Mumbole, H., Ismail, M. H., Choo, A., Baker, O., Atha, K., Mei, S. C. S., Raj, A., Anand, P., Aung, N., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15475 · Cited by 11
“14 Among the 10 observational studies, four were prospective 34,36,38,43 and six were retrospective cohort studies.”
Chen, A. X., Radhakutty, A., Zimmermann, A., Stranks, S. N., Thompson, C. H., & Burt, M. G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110557 · Cited by 7
Self-citationWinhofer, Y., Wolf, P. S., Fellinger, P., Tura, A., Hillebrand, P., Staufer, K., Trauner, M., Jaksch, P., Muraközy, G., Kautzky‐Willer, A., et al. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0461 · Cited by 7
Steroid-induced diabetes in the paediatric population
Drucis, M., Irga‐Jaworska, N., & Myśliwiec, M. (2018) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2018.80995 · Cited by 8
“Of course, if during intensive treatment the patient receives steroid doses in the evening or at night, fasting glycaemia levels will also be abnormal [7].”
BackgroundAn open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
Miyawaki, Y., Sada, K., Asano, Y., Hayashi, K., Yamamura, Y., Hiramatsu, S., Ohashi, K., Morishita, M., Watanabe, H., Matsumoto, Y., et al. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1817-6 · Cited by 9
Valenzano, M., Lepore, G., & Grassi, G. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01724-8 · Cited by 6
“Most of the time, when oral steroids are given in the early morning, blood glucose begins to deteriorate in the late morning, usually peaks in the afternoon and then falls overnight [2, 5].”
BackgroundJalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Cardoza-Jiménez, K. J., Carranza-Zavala, B., Franco, K. M., Espinoza‐Morales, F., & Mejia, C. R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102188 · Cited by 7
“In addition, it has been reported that, in hospitalized patients with diabetes, the administration of corticosteroids produces an exacerbation of glycemic excursions [7,8] and generates sustained hyperglycemia [9].”
Agarwal, S., Demidowich, A. P., Soliman, D., Umpierrez, G. E., & Galindo, R. J. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251364276 · Cited by 7
“56 Receiving a single intermittent dose of dexamethasone (eg, a single dose of intravenous dexamethasone every two weeks) can also result in a steady but profound glycemic increase within 3 hours of GC administration and last 24 to 36 hours, before returning to baseline.”
Morikawa, L. L., Nery, M., & Toyoshima, M. T. K. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.024 · Cited by 6
Diabetes and cancer: glucose control impact on survival and tumor outcomes
Ruggeri, R. M., Grossrubatscher, E. M., Arrivi, G., Ciocca, E., Filice, A., Golisano, B., Mazzilli, R., Prinzi, N., Colao, A., Faggiano, A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10040-x · Cited by 7
He, X., Duan, G., Lu, J., Wang, Y., Cai, J., Tong, Y., Wu, W., Ma, X., Qi-ming, F., & Zhou, J. (2024) · Endocrine · doi:10.1007/s12020-024-03841-0 · Cited by 7
“Prior to the COVID-19 pandemic, study data were most extensive for prednisolone-induced hyperglycemia [21 – 23], which is characterized by signi fi cant glucose elevation in afternoon and evening, but not overnight, when pre-dnisolone was administered in the morning.”
Glucocorticoid prescribing in neurology
Jones, A. P., Debono, M., Walsh, J., Smith, C., Hunt, L., & McKevitt, F. M. (2024) · Practical Neurology · doi:10.1136/pn-2023-003855 · Cited by 5
Management of hyperglycemia in the neurosurgery patient
Daniel, R., Villuri, S., & Furlong, K. (2017) · Hospital Practice · doi:10.1080/21548331.2017.1370968 · Cited by 8
Montes, E. G., Mansani, F. P., Toledo, A. D. O., Schafranski, M. D., Zardo, B. Q., dos Santos, F. A., Grassiolli, S., Calixto, L. D. F., da Costa, R. L., Netto, F. D. F., et al. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00892-x · Cited by 6
Gordon, C., Kamel, B., McKeon, L., Brooks, D., & Schulman‐Rosenbaum, R. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100123 · Cited by 5
“Besides the potency and duration of steroid therapy, other risk factors for steroid-induced hyperglycemia include pre-diabetes, family history of diabetes, gestational diabetes, older age, length of hospital stay, and elevated c-reactive protein [6,8,9,11].”
BackgroundYates, C. J., Barraclough, K. A., McWhinney, B. C., Ungerer, J. P. J., Fullinfaw, R. O., Colman, P. G., Fourlanos, S., & Cohney, S. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31829daae4 · Cited by 6
Magnolol alleviates inflammation and oxidative stress in COPD via MAPK and Nrf2 signaling pathways
Liu, S., Huang, C., Wu, Z., Mei, X., Li, S., Xing, Y., Zhong, Y., Mi, B., Wang, Y., & Tang, X. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100264 · Cited by 5
Shimizu, N., Hayashi, A., Ito, S., Suzuki, A., Fujishima, R., Matoba, K., Wada, T., Takano, K., Katagiri, M., & Shichiri, M. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0540 · Cited by 4
“The reason for the lower accuracy of isCGM in COVID-19 patients than previously reported may be due to the inflammatory condition caused by COVID-19 and/or changes in interstitial fluid caused by steroid use [25].”
BackgroundWhyte, M., Vas, P. R. J., & Umpleby, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649405 · Cited by 4
Kitamura, T., Otsuki, M., Tamada, D., Tabuchi, Y., Mukai, K., Morita, S., Kasayama, S., Bando, Y., Shimomura, I., & Koga, M. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.09.007 · Cited by 4
“Fasting plasma glucose is slightly elevated or normal but postprandial plasma glucose is markedly high [31,32].”
BackgroundManagement of Glucocorticoid‐Induced Diabetes and/or Hyperglycemia
Kim, H. N., & Mathioudakis, N. N. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch38 · Cited by 4
Management of Steroid-induced Hyperglycemia
Suh, S., & Park, M. K. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.3.174 · Cited by 3
“기존의 체중에 근거한 기저 인슐린용량 설 정은 SIDM에서는 저혈당 발생의 위험성이 높으므로 환자 의 혈당변동성에 대해서 지속적인 감시가 필요하다[35].”
Zhou, Y. G., Zhao, Y., Yuan, T., Jiang, N., Dong, Y., Yang, Y., Wang, L., Zhao, J., Min, L., & Zhao, W. (2017) · Endocrine Practice · doi:10.4158/ep171820.or · Cited by 6
Morganstein, S. I., Morganstein, D. L., & Morganstein, L. R. (2020) · BDJ · doi:10.1038/s41415-020-2238-7 · Cited by 3
Brooks, D., & Levy, C. J. (2021) · INTERNATIONAL JOURNAL OF DIABETES & METABOLIC SYNDROME · doi:10.52106/2771-1331.1003 · Cited by 3
Lobnig, B. M. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0772-2 · Cited by 3
High prevalence of undiagnosed impaired glucose tolerance in patients with rheumatoid arthritis
Warman, N. ‘. E., Baharuddin, H., Rahman, T. H. A., Ismail, N. B., Ch’ng, S. S., Rosman, A., & Ghani, R. A. (2022) · SAGE Open Medicine · doi:10.1177/20503121221088088 · Cited by 3
Tanabe, K., Ishihara, T., Nakamura, Y., Yoshimura, N., Yamaguchi, S., Suetsugu, R., & Iida, H. (2020) · Pain Physician · doi:10.36076/ppj.2021.24.e87-e93 · Cited by 6
Lakhani, O., & Patel, S. D. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0649-7 · Cited by 2
“A number of studies have shown that morning prednisolone produces a glycemic onset after 2–4 h, a peak 6–8 h after administration and the effect wears off about 12–14 h after the morning dose [4].”
BackgroundSotani, R., Kusuhara, S., Hirota, Y., Kim, K. W., Matsumiya, W., Ogawa, W., & Nakamura, M. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06275-y · Cited by 3
“This pattern of hyperglycemia is consistent with that reported by Burt et al., who investigated the circadian effects of prednisolone on glucose concentrations in hospitalized patients with chronic obstructive pulmonary disease without known diabetes using CGM [14].”
ResultSteroid Induced Diabetes Mellitus
Wardani, I. S. (2023) · Unram Medical Journal · doi:10.29303/jk.v12i1.4350 · Cited by 4
Trummer, C., Pandis, M., Theiler‐Schwetz, V., Schmitt, L., Obermayer-Pietsch, B. M., Gellner, V., Simon, A., & Pilz, S. (2024) · Endocrine · doi:10.1007/s12020-024-03832-1 · Cited by 2
“We are aware that the risk of short-term glucocorticoid treatment is likewise very low but potential adverse effects cannot be excluded entirely [22, 23].”
BackgroundBöyük, B., Akın, S., Aladağ, N., Işık, A. C., Erman, H., Özgür, Y., Topal, M., Karademir, N., Uysal, B. T., Ozbilgehan, B., et al. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002363 · Cited by 3
[Endocrinometabolic disorders in chronic obstructive pulmonary disease].
Torres‐Sánchez, I., Valenza, M. C., Fernando Carrasco, N., Martos, I. C., Valenza‐Demet, G., & Cano-Capellaci, M. (2013) · PubMed · doi:10.3305/nh.2013.28.4.6573 · Cited by 2
Chronic obstructive pulmonary disease exacerbations, ‘Sugar Sugar’, what are we monitoring?
del Campo, M. M., Roberts, G. W., & Cooter, A. (2015) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1132 · Cited by 2
Self-citationAzacitidine-induced hyperglycaemia
Morton, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231903 · Cited by 2
Silveira, D. (2020) · BDJ · doi:10.1038/s41415-020-2239-6 · Cited by 2
Management of Hyperglycemia in the Neurosurgery Patient
Daniel, R., Villuri, S., & Furlong, K. (2020) · JHN journal · doi:10.29046/jhnj.015.1.005 · Cited by 1
Welsch, S., Mailleux, V., de Beaulieu, P. L. H., Ranguelov, N., Godefroid, N., Robert, A. R., Stéphenne, X., Scheers, I., Reding, R., Sokal, E. M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1080905 · Cited by 5
王, 东. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134974 · Cited by 1
Inpatient Glucocorticoid-Induced Hyperglycemia
Paul, E., & Brooks, D. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_12 · Cited by 1
Chen, A. X., Radhakutty, A., Thompson, C. H., & Burt, M. G. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-004963 · Cited by 2
Self-citationAn, Y., Yu, X., Wang, C., Yu, X., Zheng, J., & Lin, H. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1703853 · Cited by 1
Glucocorticoid‐Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most
Burt, M. G., Khalili, F., Radhakutty, A., & Chen, A. X. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70756 · Cited by 1
Self-citationIndividuelle Therapieziele bei Glukokortikoid-induziertem Diabetes mellitus – „Steroiddiabetes“
Lobnig, B. M. (2012) · Der Diabetologe · doi:10.1007/s11428-011-0819-4 · Cited by 1
Chronisch obstruktive Lungenerkrankung und Diabetes
Krüger, S., & Keymel, S. (2018) · Der Diabetologe · doi:10.1007/s11428-017-0294-7 · Cited by 1
Using Continuous Glucose Monitoring for Steroid-Induced Diabetes
Lu, J., & Jia, W. (2018) · Springer eBooks · doi:10.1007/978-981-10-7074-7_17 · Cited by 1
Selimov, A. Y., Eliseeva, L. N., Kurinnaya, V. P., & Петрович, О. С. (2019) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2019-26-1-209-218 · Cited by 1
Hoefsloot, S., Urbanski, G., Lacout, C., Bouvard, B., & Lavigne, C. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.03.326 · Cited by 5
Toyoshima, M. T. K. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-11012022-135720 · Cited by 1
The Efficacious and Safe Treatment for Steroid-Induced Hyperglycemia
Yanai, H. (2018) · Journal of Endocrinology and Metabolism · doi:10.14740/jem492w
Effets métaboliques des hypercorticismes exogènes
Fardet, L. (2013) · Obésité · doi:10.1007/s11690-013-0361-1
Het beleid bij diabetes mellitus in de palliatieve (terminale) fase
Gerritsen, H. (2014) · Bijblijven · doi:10.1007/s12414-014-0006-9
Wenn Leber, Lunge & Co. die Zuckerwerte erhöhen
Lobnig, B. M., & Lydtin, H. (2013) · CME · doi:10.1007/s11298-013-0290-1
Jecht, M. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0224-8
“Diese Arbeiten deuten darauf hin, dass die blutzuckersenkende Wirkung von Insulin v. a. zwischen Mittag und dem Abend stattfinden sollte.”
BackgroundWilkens, H., & Leser, D. (2017) · Der Pneumologe · doi:10.1007/s10405-017-0122-1
“Typischerweise sind bei einer morgendlichen Gabe der Steroide die Blutzucker-Nüchternwerte normal,Mittagswerte deutlich und Abendwerte leicht erhöht [11].”
BackgroundJafar, N. S., Edriss, H., Islam, E. A., & NUGENT, K. M. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Prol, A. R. (2017) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14032.2017.579336
AYDOĞAN, O., ÇORAKÇI, B. D., Erboy, F., Altınsoy, B., Çağlar, E., & Bayraktaroğlu, T. (2018) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tjdo.2018.179
“Bu nedenle ilk 48 saatteki glikoz testi ile hiperglisemi olanların çoğu saptanır(14-16).”
BackgroundAhmed, S., Bordhan, P., Imam, H., & Salma, U. (2020) · Medicine Today · doi:10.3329/medtoday.v32i1.44835
Galindo, D. E. B. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/12798
Bakılan, F., Uçan, A., & Ortanca, B. (2021) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.844052
Analysis of Clinical Characteristics of Glucose Metabolism in 118 Patients with Cushing’s Syndrome
怀, 宙. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.113142
Lenferink, A. (2017) · University of Twente Research Information · doi:10.3990/1.9789036543736 · Cited by 1
Het beleid bij diabetes mellitus in de palliatieve (terminale) fase
Gerritsen, H. (2014) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-0826-2_13
Li, J., Shi, J., Dong, Y., Yuan, T., Fu, Y., Xu, T., & Zhao, W. (2021) · Research Square · doi:10.21203/rs.3.rs-923851/v1
Use of Insulin during the Current Pandemic
Chowdhury, S., Hasan, B. M., Shahraj, C., Clocchiatti‐Tuozzo, S., Rasool, M. H. U., Desai, S., Sekzer, C., & Kumar, T. P. (2022) · International Archives of Endocrinology Clinical Research · doi:10.23937/2572-407x.1510031
Diabètes pharmaco-induits : quatre classes médicamenteuses au cœur de notre pratique clinique
Scheen, A. J., & Fève, B. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.06.004 · Cited by 1
Progress in the Protective Mechanism of Salidroside in Chronic Obstructive Pulmonary Disease
Ruan, M., & Hu, R. (2023) · International Journal of Clinical and Experimental Medicine Research · doi:10.26855/ijcemr.2023.04.001
Hyperglycemia and Diabetes in the Posttransplant Patient
Dowlatshahi, S., Zahid, M., & Sadhu, A. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_20
An, Y., Wang, C., Yu, X., Yu, X., Xiao, Q., Chen, Y., Liu, T., Zheng, J., Lin, H., & Wang, F. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855142
Kato, A., Fuwa, M., Asano, M., Mori, I., Iida, S., Okada, H., Uno, Y., Fujioka, K., & Morita, H. (2024) · Internal Medicine Journal · doi:10.1111/imj.16547
Sandhu, H., Gilden, J. L., & Wentz, L. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407663.case33
Efficacy and Side Effect of Different Doses of Glucocorticoids on Sudden Deafness
He, Y., Zhi, L., Feng, Y., Li, S., Liu, Q., Jiang, Z., & Zhong, C. (2025) · Current Therapeutic Research · doi:10.1016/j.curtheres.2025.100794 · Cited by 1
“Burt et al 16 reported that in patients with chronic obstructive pulmonary disease accompanied by diabetes, short-term systemic prednisolone ( ≥ 20 mg/d, orally) treatment can increase the blood glucose.”
Lee, S. E., Park, J., Kim, D., Lee, H.-A., Kang, Y. S., Yoon, Y.-S., Jeong, Y. J., Choi, H. S., & Kim, K. (2025) · Biomedicines · doi:10.3390/biomedicines13051101
“In another study, all patients with pre-existing diabetes experienced hyperglycemia following glucocorticoid treatment [6].”
InfluentialFerrière, A., & Tabarin, A. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.07.002
Hyperglycémie induite par l’analogue de somatostatine pasiréotide au cours de la maladie de Cushing
Reznik, Y., Bisot-Locard, S., & Vergès, B. L. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30072-9
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285362
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285374
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285368
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285341
Uchinuma, H., Ichijo, M., Harima, N., & Tsuchiya, K. (2020) · Figshare · doi:10.6084/m9.figshare.12270095
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285350
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285329
Peng, Y., Zhong, G.-C., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · Figshare · doi:10.6084/m9.figshare.12285359
TAKIZAWA, H., Uzawa, H., Masuzawa, M., & Ogawa, O. (2026) · Cureus · doi:10.7759/cureus.104228
“During prednisolone treatment, fasting glucose is typically normal to mildly elevated, with hyperglycemia emerging from the afternoon to evening [12].”
Cheung, N. W., Hor, A., Marschner, S. L., Chan, C., Min, H., Lee, L., Hng, T., Rhou, Y. J. J., Wu, Y., Wang, M., et al. (2026) · Diabetology · doi:10.3390/diabetology7050094
“Similarities in the time course of action of prednisone and isophane (Neutral Protamine Hagedorn) insulin [2,3] have led to the latter’s use in the management of GIH.”
Continuous Glucose Monitoring Profiles in Children Receiving High-Dose Glucocorticoid Treatment
Lukka, M., Tillmann, V., & Peet, A. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552876
Metadata
- Authors
- Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N.
- Affiliations
- Flinders University (AU)
- Repatriation General Hospital (AU)
- Corresponding author
- Burt, Morton G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1789-1796
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2042010542
- Cited by
- 203
- References
- 22
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 14 · 2022: 12 · 2021: 16 · 2020: 25 · 2019: 14 · 2018: 17 · 2017: 10 · 2016: 13 · 2015: 9 · 2014: 13 · 2013: 18 · 2012: 8
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- prednisolone, glucocorticoid-induced hyperglycemia, Cushing's syndrome, chronic obstructive pulmonary disease, COPD exacerbations, continuous glucose monitoring, interstitial glucose, postprandial hyperglycemia, diabetes mellitus, glucocorticoid adverse effects, timing of corticosteroid administration
- MeSH terms
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Blood Glucose, Cross-Sectional Studies, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Male, Middle Aged, Prednisolone, Prospective Studies, Blood Glucose Self-Monitoring, Patient Selection, Postprandial Period, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.